Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

Pungor E Jr, Files JG, Gabe JD, Do LT, Foley WP, Gray JL, Nelson JW, Nestaas E, Taylor JL, Grossberg SE.

J Interferon Cytokine Res. 1998 Dec;18(12):1025-30.

PMID:
9877445
2.

Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.

Deisenhammer F, Reindl M, Berger T.

J Interferon Cytokine Res. 2001 Mar;21(3):167-71.

PMID:
11331039
3.

Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay.

Files JG, Hargrove D, Delute L, Cantillon M.

J Interferon Cytokine Res. 2007 Aug;27(8):637-42.

PMID:
17784815
4.

Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.

Wadhwa M, Subramanyam M, Goelz S, Goyal J, Jethwa V, Jones W, Files JG, Kramer D, Bird C, Dilger P, Tovey M, Lallemand C, Thorpe R.

J Interferon Cytokine Res. 2013 Nov;33(11):660-71. doi: 10.1089/jir.2012.0079. Epub 2013 Jul 13.

5.

Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.

Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F.

J Immunol Methods. 2007 Apr 10;321(1-2):19-31. Epub 2007 Feb 20.

PMID:
17335844
6.

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT.

Neurology. 2003 Feb 25;60(4):634-9.

PMID:
12601105
7.

Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.

Monzani F, Meucci G, Caraccio N, Saviozzi M, Casolaro A, Moscato G, Lombardo F, Mosti S, Scagnolari C, Bruschi F, Antonelli G, Ferrannini E, Murri L.

J Interferon Cytokine Res. 2002 Jul;22(7):773-81.

PMID:
12184915
8.

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.

Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5.

PMID:
24009164
9.

ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.

Brickelmaier M, Hochman PS, Baciu R, Chao B, Cuervo JH, Whitty A.

J Immunol Methods. 1999 Jul 30;227(1-2):121-35.

PMID:
10485260
10.

A novel sensitive and selective bioassay for human type I interferons.

Files JG, Gray JL, Do LT, Foley WP, Gabe JD, Nestaas E, Pungor E Jr.

J Interferon Cytokine Res. 1998 Dec;18(12):1019-24.

PMID:
9877444
11.

Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.

Grossberg SE, Oger J, Grossberg LD, Gehchan A, Klein JP.

J Interferon Cytokine Res. 2011 Mar;31(3):337-44. doi: 10.1089/jir.2010.0038. Epub 2011 Jan 12.

PMID:
21226608
12.

Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.

Cludts I, Meager A, Thorpe R, Wadhwa M.

J Immunol Methods. 2013 Sep 30;395(1-2):37-44. doi: 10.1016/j.jim.2013.06.008. Epub 2013 Jul 2.

13.

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study.

Pachner AR, Warth JD, Pace A, Goelz S; INSIGHT investigators.

Neurology. 2009 Nov 3;73(18):1493-500. doi: 10.1212/WNL.0b013e3181bf98db. Erratum in: Neurology. 2010 Mar 16;74(11):936.

PMID:
19884577
14.

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.

Cook SD, Quinless JR, Jotkowitz A, Beaton P; Neutralizing Antibody Study Group.

Neurology. 2001 Sep 25;57(6):1080-4.

PMID:
11571337
15.

Antibodies against interferon-beta in multiple sclerosis.

Aarskog NK, Marøy T, Myhr KM, Vedeler CA.

J Neuroimmunol. 2009 Jul 25;212(1-2):148-50. doi: 10.1016/j.jneuroim.2009.04.012. Epub 2009 May 20.

PMID:
19467718
16.

Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.

Farrell RA, Espasandin M, Lakdawala N, Creeke PI, Worthington V, Giovannoni G.

Mult Scler. 2011 Nov;17(11):1333-40. doi: 10.1177/1352458511412654. Epub 2011 Jun 17.

PMID:
21685230
17.
18.

Immunogenicity of an interferon-beta1a product.

Kauffman MA, Sterin-Prync A, Papouchado M, González E, Vidal AJ, Grossberg SE, Chuppa S, Odoriz B, Vrech C, Diez RA, Ferro HH.

Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):499-504.

PMID:
21658324
19.

The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels.

Grossberg SE, Kawade Y, Grossberg LD.

J Interferon Cytokine Res. 2009 Feb;29(2):93-104. doi: 10.1089/jir.2008.0043.

20.

Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.

Jensen PE, Sellebjerg F, Søndergaard HB, Sørensen PS.

Eur J Neurol. 2012 Oct;19(10):1311-7. doi: 10.1111/j.1468-1331.2012.03721.x. Epub 2012 May 5.

PMID:
22564111

Supplemental Content

Support Center